82
Participants
Start Date
October 25, 2019
Primary Completion Date
December 31, 2025
Study Completion Date
March 31, 2026
Durvalumab
1500 mg IV on day 1 of 4 week cycle every 4 weeks for 12 months
Hospital Clinico San Carlos, Madrid
Hospital 12 de Octubre, Madrid
Hospital Universitario La Paz, Madrid
Hospital Madrid Norte Sanchinarro, Madrid
Hospital Universitario Marques de Valdecilla, Santander
Instituto Valenciano de Oncologia, Valencia
Tom Baker Cancer Centre, Calgary
Cross Cancer Institute, Edmonton
BCCA - Vancouver Cancer Centre, Vancouver
Health Sciences North, Greater Sudbury
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton
Kingston Health Sciences Centre, Kingston
London Regional Cancer Program, London
Stronach Regional Health Centre at Southlake, Newmarket
Ottawa Hospital Research Institute, Ottawa
Thunder Bay Regional Health Sciences Centre/, Thunder Bay
University Health Network, Toronto
The Jewish General Hospital, Montreal
The Research Institute of the McGill University, Montreal
Allan Blair Cancer Centre, Regina
Saskatoon Cancer Centre, Saskatoon
Hospital Clinic i Provincial, Barcelona
Hospital de la Santa Creu i Sant Pau, Barcelona
Royal Devon and Exeter Hospital, Exeter
Royal Cornwall Hospitals NHS Trust, Cornwall
Royal Preston Hospital, Lancashire
Charing Cross Hospital, London
The Christie NHS Foundation Trust, Manchester
The Royal Marsden NHS Foundation Trust - Sutton, Surrey
University Hospital Southampton NHS Foundation Trust, Southampton
Nottingham University Hospitals City Hospital Campus, Nottingham
Collaborators (1)
AstraZeneca
INDUSTRY
Canadian Cancer Trials Group
NETWORK